KP Tissue Inc.

Thank you. . . . . Thank you. We'll be right back. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. Thank you. . . . . . Thank you. Thank you. Thank you. . . . Thank you.

Good morning and welcome to KP Tissue's fourth quarter 2025 results conference call. Note that today's call is being recorded for replay. All participants are currently listen-only mode. Following the presentation, we will conduct a question and answer session. Instructions will be provided at that time for you to queue up for questions. And if at any time you have difficulties hearing the conference, please press star followed by zero for operator assistance. I will now turn the call over to Doris Gerbit, Director of Investor Relations. You may begin your conference.

Thank you, Operator. Good morning, everyone, and thank you for joining us to review Kruger Products' fourth quarter 2025 financial results. With me this morning is Dino Bianco, the CEO of KP Tissue and Kruger Products, and Michael Key, the CFO of KP Tissue and Kruger Products. Today's discussion will include certain forward-looking statements. Actual results could differ materially from these forward-looking statements due to known and unknown risks and uncertainties. A list of risk factors can be found in our public filing. In addition, today's discussion will include certain non-GAAP financial measures. The reconciliation of these non-GAAP financial measures to the most comparable GAAP measure can be found in our MD&A. The press release reporting our Q4 2025 results was published this morning. and will be available on our website at kptissuelink.com. The financial statements and MD&A will also be posted on our website and on CDAR+. The investor presentation to accompany today's discussion can be found in the investor relations section of our website. I will now turn the call over to our CEO, Dino Bianco. Dino?